Month: January 2022

New class begins March 14th; program targets employment opportunities across central New Jersey Parsippany, NJ, Jan. 26, 2022 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training for more than 75 years, announces the introduction of a Dental Assisting career training program at the Iselin, NJ campus. Set to address a projected gap of more than 14,000 job openings in New Jersey*, the program is the fourth option for healthcare education at the central New Jersey location along with Medical Assisting, Practical Nursing and Patient Care Technician training. “We know that in New Jersey, the market for Dental Assistants is strong,” says Lincoln Tech President and CEO Scott Shaw. “The shortage of qualified Dental Assistant candidates is a prominent part of the...

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences. B. Riley Virtual Oncology Investor Conference Thursday, January 27, 20228:00AM PT/11:00AM ET 4th Annual Guggenheim Oncology DayWednesday, February 9, 20221:00PM PT/4:00PM ET Cowen 42nd Annual Health Care ConferenceMonday, March 7, 20228:10AM PT/11:10AM ET Oppenheimer’s 32nd Annual Healthcare ConferenceTuesday, March 15, 2022Timing to be posted on Company’s website Webcasts will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section....

SAN FRANCISCO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE:DLB) will release financial results for the first quarter (Q1) of fiscal 2022 after the close of regular trading on Thursday, February 3, 2022. Members of Dolby management will lead a conference call open to all interested parties to discuss Q1 fiscal 2022 financial results for Dolby Laboratories at 1:30 p.m. PT (4:30 p.m. ET) on Thursday, February 3, 2022. Access to the teleconference will be available at http://investor.dolby.com/ or by dialing 1-844-200-6205 (or dialing +1-929-526-1599 for international callers), and entering confirmation code 003699. A replay of the call will be available from 4:30 p.m. PT (7:30 p.m. ET) on Thursday, February 3, 2022, until 10:30 p.m. PT on Thursday, February 10, 2022 (1:30 a.m. ET on Friday, February 11, 2022),...

JOYSOL™, a CBD brand developed by Clever Leaves’ US consumer packaged goods division, Herbal Brands, is now available onlineJoySol Product FamilyJoySol Product FamilyBOCA RATON, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today announced its entrance to the U.S. CBD market through the launch of its consumer-oriented CBD line JoySol™. JoySol is produced by Arizona-based Herbal Brands, Inc. (“Herbal Brands”), an established consumer goods manufacturer, wholesaler and direct-to-consumer e-tailer and a wholly-owned subsidiary of Clever Leaves. Clever Leaves’ consumer brands division is introducing JoySol with high-quality CBD, minor cannabinoids...

HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and take this opportunity to share our accomplishments in 2021 and our planned path forward. We believe 2022 will be a transformative year for Processa as our multi-asset pipeline continues to mature and we achieve important clinical milestones. Our pipeline is different from that of other biotech companies because each of our drugs have a “de-risked”...

Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2022 ended December 31, 2021 on Tuesday, February 8, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, February 8, 2022. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011. The conference call will be simultaneously webcast and can be accessed at https://www.webcaster4.com/Webcast/Page/2199/44375...

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm – 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID OCALA, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced it will participate in the Solve M.E. Diagnostics and Treatments Webinar: “Ampligen: A General Overview and the Plan for ME/CFS & Long Covid,” being held on Thursday, January 27, 2022 from 2:00 – 3:00 pm ET. Ampligen...

U.S. cybersecurity services firm promotes experienced operations professional SCOTTSDALE, Ariz., Jan. 26, 2022 (GLOBE NEWSWIRE) — Cerberus Cyber Sentinel Corporation (Nasdaq: CISO), a Managed Compliance and Cybersecurity Provider (MCCP) based in Scottsdale, Ariz., announced that Kyle Young has been promoted to executive vice president, operations. Young will be responsible for all business operations and work closely with CEO David Jemmett and CFO Deb Smith. Previously, Young served as vice president, operations, for Cerberus Sentinel. He has provided the operational due diligence on acquisitions, successfully integrating nine organizations into the company. He also has overseen the successful migration of the company and subsidiaries to NetSuite. Prior to joining Cerberus Sentinel in February 2021, Young served as vice president,...

– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO, ONTARIO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided a corporate update and business outlook. “Over the course of 2021, we in-licensed six new pre-clinical development programs, four potential therapeutics and two potential vaccines, all of which were added to our development pipeline based on their potential to represent significant individual market opportunities,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna. “We...